The APS appreciate that interest in the therapeutic use of psychedelics and psychedelics in general is increasing. We will continue to advocate strongly for legal reform to allow people to access these substances in a safe and well informed manner. We will continue to build a strong community of people interested in psychedelics in Australia.

As many of you will know, Mind Medicine Australia (MMA) has submitted another application to the Therapeutic Goods Administration (TGA) to make changes to the scheduling of psilocybin and MDMA.

A Psychedelic Harm Reduction Webinar-Great for newbies!!

In this webinar you will learn:

-What psychedelic harm reduction is

-Why harm reduction is an important part of the psychedelic journey

-Tips and tools to effectively reduce risk in your own psychedelic experience

The main mushroom season is upon us again in southern Australia, as winter approaches, rainfall increases and temperatures drop. Fungi grow at other times of the year, but the late autumn/winter season is the time of greatest abundance and diversity. As mycophiles venture out into nature seeking mushrooms to gather, we hope that people do so responsibly by bearing in mind a few things.

As mushroom season approaches in southern parts of Australia, we have some helpful resources on southern Australian Psilocybe species, courtesy of fungi educator, mycologist and APS committee member Caine Barlow.

If you follow the APS or similar pages on social media, there’s a good chance you will have seen targeted advertising about trial matching services that aim to match would-be participants to clinical trials of psychedelics. After some discussion, we decided it would be a good idea to offer the APS’s take on these services.

TGA scheduling decisions are highly bureaucratic and often confusing, so let us help you break it down to something more understandable, so you know exactly what is and is not being proposed.

Psychedelics helped me move through the distractions and patterns of my past and allowed me to consider that I have a future.

The intention of this piece is to articulate the impact that the psychedelic experience has had on my life. I am writing to give myself clarity, and to help me explain to others why I sought out this experience; what happened to me as a result; and to give some perspective as to why I still use psychedelic drugs today.

Through PRISM, Martin and his colleagues have been advocating since 2011 for mental health research using psychedelic compounds in Australia, and in doing so, have established connections with researchers in the USA, Canada, the Czech Republic, Germany, the Netherlands, New Zealand and the United Kingdom. In the course of planning and seeking approvals for two clinical trials, one of MDMA-assisted psychotherapy for the treatment of PTSD and the other of psilocybin-assisted psychotherapy for the treatment of anxiety and depression associated with terminal illness, Martin has become familiar with the Australian regulatory and research governance landscape.

“It was here that my journey to true, lasting healing began… but first I had to find a drug dealer. “

The fourth seminar in Perth’s Altered States series took place in June at the University of Western Australia and was led by Tobias Penno and Dr. Chris Letheby, both of whom have conducted academic research into connections between psychedelics and contemplative practices such as mindfulness meditation.